Clinical Trial Update: Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2) [Phase 3]

View source ↗

Summary

RESIST-2 is a Phase 3 trial comparing tipranavir/ritonavir to a genotypically defined protease inhibitor/ritonavir in HIV-infected patients; the study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• tipranavir/ritonavir (tipranavir/ritonavir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2009-12-23